- Home
- MTEK vs IMNN Comparison
MTEK vs IMNN Comparison
Compare MTEK & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEK
- IMNN
- Stock Information
- Founded
- MTEK 2008
- IMNN 1982
- Country
- MTEK Israel
- IMNN United States
- Employees
- MTEK N/A
- IMNN N/A
- Industry
- MTEK
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- MTEK
- IMNN Health Care
- Exchange
- MTEK Nasdaq
- IMNN Nasdaq
- Market Cap
- MTEK N/A
- IMNN 12.1M
- IPO Year
- MTEK 2022
- IMNN 1985
- Fundamental
- Price
- MTEK $3.26
- IMNN $0.60
- Analyst Decision
- MTEK
- IMNN Buy
- Analyst Count
- MTEK 0
- IMNN 2
- Target Price
- MTEK N/A
- IMNN $14.00
- AVG Volume (30 Days)
- MTEK 166.1K
- IMNN 1.3M
- Earning Date
- MTEK 08-27-2025
- IMNN 08-13-2025
- Dividend Yield
- MTEK N/A
- IMNN N/A
- EPS Growth
- MTEK N/A
- IMNN N/A
- EPS
- MTEK N/A
- IMNN N/A
- Revenue
- MTEK $6,078,953.00
- IMNN N/A
- Revenue This Year
- MTEK N/A
- IMNN N/A
- Revenue Next Year
- MTEK N/A
- IMNN N/A
- P/E Ratio
- MTEK N/A
- IMNN N/A
- Revenue Growth
- MTEK 50.80
- IMNN N/A
- 52 Week Low
- MTEK $1.48
- IMNN $0.37
- 52 Week High
- MTEK $6.47
- IMNN $3.65
- Technical
- Relative Strength Index (RSI)
- MTEK 60.44
- IMNN 35.40
- Support Level
- MTEK $3.00
- IMNN $0.70
- Resistance Level
- MTEK $3.42
- IMNN $0.86
- Average True Range (ATR)
- MTEK 0.27
- IMNN 0.07
- MACD
- MTEK 0.00
- IMNN -0.03
- Stochastic Oscillator
- MTEK 67.03
- IMNN 0.05
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).